

## **Pricing and Reimbursement in Japan: Costly healthcare system inefficiencies increase the focus on healthcare cost containment**

---

Published: 2006-NOV-09

Pages: 65

Format: PDF & SlidePack

Price: 3800 USD

### **Description**

#### Introduction

The government has relied on simple P&R tools to contain rising healthcare costs and provide a reasonable level of healthcare. However, factors such as a healthier elderly population are masking healthcare system inefficiencies, boosting healthcare costs and increasing the focus on cost containment. Although the rise in drug spending is slowing down, it remains a visible cost containment target.

#### Scope

- \*Overview of the Japanese healthcare system, detailing trends shaping healthcare provision including how P&R fits in
- \*In-depth analysis of the Japanese P&R infrastructure, examining how P&R tools are used to contain costs
- \*Examination of macro trends shaping healthcare provision and the P&R environment
- \*Identification of future trends shaping P&R tool use and healthcare evolution in Japan

#### Highlights

Over the last decade, biennial drug price cuts and increasing patient co-payment levels have been the key tools used to contain pharmaceutical expenditure.

In the future, a range of factors will impact the P&R environment, including greater generic uptake, the wider adoption of a prospective payment reimbursement system, and determining a solution to providing the elderly with adequate yet cost effective healthcare provision.

A range of macro trends are also impacting drug prescription and P&R, including: rising healthcare costs as a result of system inefficiencies, the fact that innovation is neither well-cultivated by Japanese drug developers nor well-rewarded by the Japanese government, and lastly the effects of an ageing population combined with a stagnant economy.

## Reasons to Purchase

\*Gain a clear understanding of the healthcare market dynamics and factors influencing healthcare provision in Japan

\*Understand the role of different P&R tools in healthcare cost containment in Japan

\*Gain insight into how P&R and more global macro trends are set to shape healthcare provision in the future

## Table of Contents

### CHAPTER 1 EXECUTIVE SUMMARY 4

Scope of the report 4

Key findings 4

### CHAPTER 2 OVERVIEW OF THE JAPANESE HEALTHCARE AND P&R SYSTEM 12

An introduction to the Japanese healthcare system 13

The government must improve efficiency and reduce costs in healthcare provision 13

High drug spending is a visible cost containment target in the Japanese healthcare system 14

An overview of the Japanese healthcare system 17

Public healthcare insurance schemes provide the majority of Japanese healthcare 17

Hospitals remain the first port-of-call for patients seeking healthcare in Japan 18

There are a number of key stakeholders that impact healthcare provision in Japan 19

Governmental stakeholders are unified under the Ministry for Health, Labor and Welfare 19

Healthcare worker and industry stakeholders 21

Gaining a price and reimbursement level in Japan: the process and the key stakeholders that affect it 23

The process of gaining a price and reimbursement level 23

Drugs qualify for fairly generous premiums if they are innovative enough 24

A wide range of premiums are available for innovative drugs, and it is slowly getting easier to meet these criteria 24

A number of healthcare stakeholders impact government P&R strategy and healthcare provision 26

The DPO and Chuikyo are the key governmental stakeholders shaping P&R 26

The influence of healthcare stakeholders in shaping healthcare reform and P&R implementation is varied 26

### CHAPTER 3 THE PRICING AND REIMBURSEMENT ENVIRONMENT IN JAPAN 28

Key reforms impacting the P&R environment 29

Biennial price cuts and patient co-payment have been the dominant P&R cost-containment tools in Japan 30

Biennial price cuts have historically had the greatest impact in restricting pharmaceutical expenditure 31

Over the past decade, the R zone has fallen, making price cuts more punitive 31

In addition to standard price cuts, extraordinary price cuts and long-listed drug price cuts also impact drugs 32

Patient co-payment is one of the most effective ways to control patient spending in Japan 33

PE analysis also plays a role in P&R in Japan, but on a more informal basis than in European markets like the UK 34

Increased DTC, the greater adoption of a prospective payment system, and increased generic uptake are all set to impact drug price following launch 35

Pharmaceutical companies exploit loopholes in advertising restrictions to capitalize on DTC and physician promotion 35

The adoption of the DRG-like diagnosis procedure combination (DPC) reimbursement system has met strong opposition but it may help to cut costs and reduce ALOS 36

There is a strong drive to increase generic uptake in Japan to help contain costs 37

Generic prescription in Japan is driven primarily on price 38

Despite cost savings available with generics, a range of factors have restricted generic uptake in Japan 39

Increased patient and physician awareness of generic drugs, greater patient participation in health management, and increased generic substitution are all helping to counteract the significant restrictors to generic uptake 40

The future is bright for generic uptake in Japan although there is still significant patient and physician resistance to overcome 41

Government use of an OTC switching category to transfer cost to patients is not effective in Japan because of the risk-averse nature of healthcare provision 42

Japanese drugs companies do not have to contend with parallel importation 43

### CHAPTER 4 KEY MACRO TRENDS INDIRECTLY IMPACTING P&R IN JAPAN 44

Healthcare costs are being driven up by a range of factors, even though drug prices appear to be falling 45

Long patient hospital stays are a significant problem in Japan and is becoming an increasingly visible focus for cost containment 46

The failure of healthcare providers to price services differentially together with financial incentives to provide outpatient care exacerbates patient selection of in-patient care as the first port of call 47

Patients have historically had little incentive to be cost-conscious 48

Physicians are under attack and have little incentive to prescribe cost-consciously 48

The wide variety of health insurance schemes has done little to help contain costs 49

Historically high drug prices have been falling in the Japanese market 51

Innovation is required for a high level of reimbursement, yet there are problems capturing and adequately rewarding innovation 52

The level of innovation required for premiums is difficult to attain 52

There has historically been relatively low R&D investment in Japan 52

Innovative drugs may bypass the lengthy approval and P&R processes which have historically slowed down access to the Japanese market 54

Restructuring R&D strategy and capitalizing on governmental financial incentives will boost innovation 54

R&D restructuring may help to capture greater innovation 54

The Japanese government needs to provide greater financial incentives for R&D and make clinical trial progression, approval and P&R assessment easier to encourage foreign investment 55

## BioMarket Group - A Global Online Aggregator of Life Science Market Research

Characteristics of Japanese society impact the healthcare service	56
The stagnant Japanese economy impacts on Japanese healthcare provision	57
CHAPTER 5 THE FUTURE OF P&R IN JAPAN	58
There are a range of factors that directly impact P&R tool use and effectiveness	58
The government should aim at making it easier for drugs companies to demonstrate innovation	58
The price cut system is set to evolve	58
Generic uptake is set to be strongly boosted	59
The number of drug types receiving high reimbursement levels is set to change	60
Reference pricing is set to become more restrictive	60
A range of factors that shape healthcare provision will also indirectly impact P&R	60
CHAPTER 6 BIBLIOGRAPHY	62
Publications and online articles	62
Datamonitor resources	63
CHAPTER 7 GLOSSARY	64
Glossary of terms	64
List of Tables	
Table 1: There are a range of premiums for new drugs which help boost drug price and reward innovation	25
List of Figures	
Figure 1: A range of factors will shape the Japanese healthcare system in the future	6
Figure 2: Healthcare spending as a proportion of GDP is below the seven major market average in Japan	13
Figure 3: Japan has historically spent a high percentage of healthcare spending on pharmaceuticals, 1980-2000	15
Figure 4: Japan's total healthcare expenditure as a percentage of GDP is not rising strongly, 1980-2003	16
Figure 5: A wide range of bodies and groups impact healthcare provision in Japan	19
Figure 6: From a healthcare and P&R perspective, there are five key bureaus in the MHLW	20
Figure 7: Reforms since 1997 have focused on a range of factors, most significantly drug prices, co-payment and medical fees	30
Figure 8: Higher biennial price cuts and a reduced R Zone percentage are increasingly punitive for drugs companies, 1992-2006	32
Figure 9: There are more disincentives than incentives for generic prescription in Japan	38
Figure 10: There are a number of factors increasing the cost of Japanese healthcare provision	46
Figure 11: There are a range of different healthcare schemes, depending on the characteristics of the person being covered	50
Figure 12: The top-13 Japanese pharma/biotech companies have had a lower R&D investment as a percentage of revenues compared to the top-38 Western pharma/biotech companies, 1999-2005	53

### Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/pricing-and-reimbursement-in-japan-costly-healthcare-system-inefficiencies-increase-the-focus-on-healthcare-cost-containment.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group  
Björnnäsvägen 21  
11419 STOCKHOLM

## Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/index.php/contacts/>

### Order Information

Please verify that the product information is correct:

Product Name: **Pricing and Reimbursement in Japan: Costly healthcare system inefficiencies increase the focus on healthcare cost containment**

Web Address: <http://www.biomarketgroup.com/market-research-report/pricing-and-reimbursement-in-japan-costly-healthcare-system-inefficiencies-increase-the-focus-on-healthcare-cost-containment.html>

Format: PDF & SlidePack

Price: 3800 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

### Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: \_\_\_\_\_

Name: \_\_\_\_\_

Email Address:\* \_\_\_\_\_

Job Title: \_\_\_\_\_

Organization: \_\_\_\_\_

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

\_\_\_\_\_

Address: \_\_\_\_\_

Zip Code: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_

Country: \_\_\_\_\_

Phone Number: \_\_\_\_\_

Fax Number: \_\_\_\_\_

### Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

**Pay by credit card:**

American Express

Master Card

Visa

Cardholder Name: \_\_\_\_\_

Expiry Date (MM/YY): \_\_\_\_\_

Card Number: \_\_\_\_\_

CVV Number: \_\_\_\_\_

**Pay by check:**

Please post the check, accompanied by this form, to:

BioMarket Group

Björnnäsvägen 21

11419 STOCKHOLM

SWEDEN

**Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: \_\_\_\_\_

Please supply purchase order number if needed:

\* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/index.php/biomarket-group-full-terms-and-conditions>

**Please fax this form to: +46-8-56849191**